SCHEMBL5145191

SCHEMBL5145191

O=C1NC(=O)C(=C(Cc2ccccc2F)c2ccc(-c3ccc(C(=O)O)c(Cl)c3)o2)N1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPA1 P27694 1/20 0.44
KDM4E B2RXH2 5/20 0.42
TDP1 Q9NUW8 4/20 0.42
KMT2A Q03164 4/20 0.42
MAPT P10636 3/20 0.42
ALDH1A1 P00352 3/20 0.42
MEN1 O00255 3/20 0.42
POLB P06746 3/20 0.42
PLA2G1B P04054 2/20 0.42
ATG4B Q9Y4P1 2/20 0.42
LMNA P02545 1/20 0.42
DNMT1 P26358 1/20 0.42
APEX1 P27695 1/20 0.42
RECQL P46063 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
KEAP1 Q14145 2/20 0.41
NFE2L2 Q16236 2/20 0.41
PKM P14618 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CTDSP1 Q9GZU7 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5145012 0.82 MEN1 (0.42) KDM4ETDP1KMT2AMAPTALDH1A1
SCHEMBL5146594 0.80 ALDH1A1 (0.55) RPA1KDM4ETDP1KMT2AMAPT
SCHEMBL6395656 0.74 KEAP1 (0.47) RPA1KDM4ETDP1KMT2AMAPT
SCHEMBL5147466 0.69 MEN1 (0.44) KDM4ETDP1KMT2AMAPTALDH1A1
SCHEMBL5147463 0.69 MEN1 (0.44) KDM4ETDP1KMT2AMAPTALDH1A1
SCHEMBL5145183 0.68 TDP1 (0.75) KDM4ETDP1KMT2AMAPTALDH1A1
SCHEMBL5145178 0.68 TDP1 (0.75) KDM4ETDP1KMT2AMAPTALDH1A1
SCHEMBL5144975 0.67 TTR (0.46) RPA1KDM4ETDP1KMT2AMAPT
SCHEMBL5144980 0.67 TTR (0.46) RPA1KDM4ETDP1KMT2AMAPT
SCHEMBL10046960 0.65 ALDH1A1 (0.51) TDP1KMT2AMAPTALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1718308-A4 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORP (CA) 2007-07-18 EP disclosed
EP-1718308-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PainCeptor Pharma Corp. (CA) 2006-11-08 EP disclosed
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2005-12-22 US disclosed
WO-2005076695-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORPORATION (CA) 2005-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity NGF, BDNF, NTRK2 RPA1 3442/4885KDM4E 4569/4885TDP1 1996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.